Randomised phase 3 study of S-1 versus capecitabine, with bevacizumab optional in both arms, in the first-line treatment of metastatic colorectal cancer (mCRC), the SALTO study of the Dutch Colorectal Cancer Group

被引：1

作者：

Kwakman, J. J. M. ^{[1
]}

Simkens, L. H. J. ^{[2
]}

Van Rooijen, J. M. ^{[3
]}

de Wouw, A. J. Van ^{[4
]}

Loosveld, O. J. L. ^{[5
]}

Creemers, G. J. M. ^{[6
]}

Hendriks, M. P. ^{[7
]}

Los, M. ^{[8
]}

Van Alphen, R. J. ^{[9
]}

Polee, M. B. ^{[10
]}

Muller, E. W. ^{[11
]}

Van der Velden, A. M. T. ^{[12
]}

Van Voorthuizen, T. ^{[13
]}

Koopman, M. ^{[14
]}

Mol, L. ^{[15
]}

Van Werkhoven, E. ^{[16
]}

Punt, C. J. A. ^{[1
]}

机构：

[1] Acad Med Ctr, Med Oncol, Amsterdam, Netherlands

[2] Maxima Med Ctr, Med Oncol, Eindhoven, Netherlands

[3] Martini Hosp, Med Oncol, Groningen, Netherlands

[4] VieCuri Med Ctr, Med Oncol, Venlo, Netherlands

[5] Amphia Hosp, Med Oncol, Breda, Netherlands

[6] Catharina Hosp, Med Oncol, Eindhoven, Netherlands

[7] Med Ctr Alkmaar, Med Oncol, Alkmaar, Netherlands

[8] St Antonius Hosp, Med Oncol, Nieuwegein, Netherlands

[9] TweeSteden Hosp, Med Oncol, Tilburg, Netherlands

[10] Med Ctr Leeuwarden, Med Oncol, Leeuwarden, Netherlands

[11] Slingeland Hosp, Med Oncol, Doetinchem, Netherlands

[12] Tergooi Hosp, Med Oncol, Hilversum, Netherlands

[13] Rijnstate Hosp, Med Oncol, Arnhem, Netherlands

[14] Univ Med Ctr Utrecht, Med Oncol, Utrecht, Netherlands

[15] Netherlands Comprehens Canc Ctr, Dept Data Management, Nijmegen, Netherlands

[16] Netherlands Canc Inst, Dept Biometr, Amsterdam, Netherlands

来源：

EUROPEAN JOURNAL OF CANCER | 2017年 / 72卷

关键词：

D O I：

10.1016/S0959-8049(17)30099-0

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

2BA

引用

页码：S5 / S5

页数：1

共 50 条

[1] Randomized phase 3 study of S-1 versus capecitabine in the first-line treatment of metastatic colorectal cancer (mCRC): The SALTO study of the Dutch Colorectal Cancer Group
Punt, Cornelis J. A.
Simkens, Lieke H.
Van Rooijen, Johan
Van de Wouw, Agnes W.
Loosveld, Olaf
Creemers, Geert-Jan
Hendriks, Mathijs P.
Los, Maartje
Van Alphen, Robbert Jeroen
Polee, Marco
Muller, Erik W.
Van der Velden, Ankie
Van Voorthuizen, Thymen
Koopman, Miriam
Mol, Linda
Kwakman, Johannes J.
van Werkhoven, Erik D.
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
[2] Randomized phase III trial of S-1 versus capecitabine in the first-line treatment of metastatic colorectal cancer: SALTO study by the Dutch Colorectal Cancer Group
Kwakman, J. J. M.
Simkens, L. H. J.
van Rooijen, J. M.
van de Wouw, A. J.
ten Tije, A. J.
Creemers, G. J. M.
Hendriks, M. P.
Los, M.
van Alphen, R. J.
Polee, M. B.
Muller, E. W.
van der Velden, A. M. T.
van Voorthuizen, T.
Koopman, M.
Mol, L.
van Werkhoven, E.
Punt, C. J. A.
ANNALS OF ONCOLOGY, 2017, 28 (06) : 1288 - 1293
[3] Updated survival analysis of the randomized phase III trial comparing S-1 versus capecitabine in the first-line treatment of metastatic colorectal cancer (SALTO) by the Dutch colorectal cancer group
Kwakman, J. J.
Van Werkhoven, E.
Simkens, L. H.
van Rooijen, J. M.
van de Wouw, A.
Ten Tije, A. J.
Creemers, G-J.
Hendriks, M. P.
Los, M.
van Alphen, R.
Polee, M. B.
Muller, E. W.
Van der Velden, A.
Van Voorthuizen, T.
Koopman, M.
Mol, L.
Punt, C. J. A.
ANNALS OF ONCOLOGY, 2019, 30
[4] Updated Survival Analysis of the Randomized Phase III Trial of S-1 Versus Capecitabine in the First-Line Treatment of Metastatic Colorectal Cancer by the Dutch Colorectal Cancer Group
Kwakman, Johannes J. M.
van Werkhoven, Erik
Simkens, Lieke H. J.
van Rooijen, Johan M.
van de Wouw, Yes A. J.
ten Tije, Albert J.
Creemers, Geert-Jan M.
Hendriks, Mathijs P.
Los, Maartje
van Alphen, Robbert J.
Polee, Marco B.
Muller, Erik W.
van der Velden, Ankie M. T.
van Voorthuizen, Theo
Koopman, Miriam
Mol, Linda
Punt, Cornelis J. A.
CLINICAL COLORECTAL CANCER, 2019, 18 (02) : E229 - E230
[5] Maintenance treatment with capecitabine and bevacizumab versus observation after induction treatment with chemotherapy and bevacizumab in metastatic colorectal cancer (mCRC): The phase III CAIRO3 study of the Dutch Colorectal Cancer Group (DCCG).
Koopman, Miriam
Simkens, Lieke H. J.
Ten Tije, Albert J.
Creemers, Geert-Jan
Loosveld, Olaf J. L.
de Jongh, Felix E.
Erdkamp, Frans
Erjavec, Zoran
van der Torren, Adelheid M. E.
Van der Hoeven, Jacobus J. M.
Nieboer, Peter
Braun, J. J.
Jansen, Rob L.
Haasjes, Janny G.
Cats, Annemieke
Wals, Jacob J.
Mol, Linda
Dalesio, Otilia
van Tinteren, Harm
Punt, Cornelis J. A.
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
[6] Phase II study of bevacizumab in combination with capecitabine as first-line treatment in elderly patients with metastatic colorectal cancer
Vrdoljak, Eduard
Omrcen, Tomislav
Boban, Marijo
Hrabar, Andina
ANTI-CANCER DRUGS, 2011, 22 (02) : 191 - 197
[7] A Study of the S-1 or Capecitabine as First-line Regimen in Patients with Metastatic Colorectal Cancer: A Real World Study
Guo, Yanan
Zheng, Tongsen
Zhang, Chunhui
Zhang, Yanqiao
JOURNAL OF CANCER, 2020, 11 (07): : 1839 - 1845
[8] Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group
Gervais, C.
Tournigand, C.
ONCOLOGIE, 2015, 17 (09) : 405 - 406
[9] Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group
Simkens, Lieke H. J.
van Tinteren, Harm
May, Anne
ten Tije, Albert J.
Creemers, Geert-Jan M.
Loosveld, Olaf J. L.
de Jongh, Felix E.
Erdkamp, Frans L. G.
Erjavec, Zoran
van der Torren, Adelheid M. E.
Tol, Jolien
Braun, Hans J. J.
Nieboer, Peter
van der Hoeven, Jacobus J. M.
Haasjes, Janny G.
Jansen, Rob L. H.
Wals, Jaap
Cats, Annemieke
Derleyn, Veerle A.
Honkoop, Aafk E. H.
Mol, Linda
Punt, Cornelis J. A.
Koopman, Miriam
LANCET, 2015, 385 (9980): : 1843 - 1852
[10] Capecitabine and bevacizumab as first-line treatment in elderly patients with metastatic colorectal cancer
J Feliu
M J Safont
A Salud
F Losa
C García-Girón
C Bosch
P Escudero
R López
C Madroñal
M Bolaños
M Gil
A Llombart
J Castro-Carpeño
M González-Barón
British Journal of Cancer, 2010, 102 : 1468 - 1473

← 1 2 3 4 5 →